Highlights

  • Monash IVF Group (ASX:MVF) reported FY26 Revenue of AUD 269.5 million.
  • Underlying EBITDA fell to AUD 53.4 million from AUD 66.3 million.
  • International segment revenue increased 15% during the financial year.
  • The 2026 Annual General Meeting is scheduled for 26 November.

Monash IVF Group Limited provides assisted reproductive services, fertility treatment and specialised women’s imaging across Australia and parts of Southeast Asia. On 16 November 2026, Monash IVF Group (ASX:MVF) was trading at AUD 0.75, unchanged during the session. Its FY26 disclosures describe lower group earnings, a decline in Australian segment profitability and growth in its international operations, while the company continues to address operating costs and service-delivery considerations.

Fertility Services and Geographic Operations

Monash IVF (ASX:MVF) offers assisted reproductive services, including in-vitro fertilisation and associated reproductive genetic testing. Its service activities also include day surgery and diagnostic imaging. The Australian segment is the largest revenue contributor; the international segment operates clinics in Malaysia, Singapore and Indonesia. Different clinic networks and patient markets contribute to distinct operating results.

The company’s financial performance reflects clinical activity, revenue per patient episode, staffing requirements, Facility utilisation and the cost of delivering regulated healthcare services. These drivers vary by geography. Growth in one region therefore does not necessarily compensate for Earnings pressure in another, particularly when fixed clinic costs remain elevated.

FY26 Revenue and Earnings

Monash IVF (ASX:MVF) reported revenue of AUD 269.459 million for the year ended 30 June 2026, compared with AUD 271.917 million in FY25, a reduction of approximately 1%. Underlying earnings before interest, tax, Depreciation and Amortisation declined to AUD 53.419 million from AUD 66.335 million, a fall of approximately 19%. Underlying net profit after tax decreased to AUD 16.111 million from AUD 27.419 million.

Reported net profit after tax was AUD 8.326 million, compared with AUD 25.676 million in FY25. The company cited lower operating earnings, additional costs responding to incidents, professional services expenses, higher depreciation and amortisation, and borrowing costs. These statutory and underlying measures answer different questions: reported profit includes items excluded from management’s underlying measure.

Australian Costs and International Growth

The Australian segment generated AUD 248.237 million in revenue, down approximately 2% year on year, and underlying earnings before interest and tax of AUD 24.821 million, a 38% decline. Monash IVF attributed the pressure to lower revenue and higher costs, including occupancy, insurance and clinical staffing that did not decrease proportionately with activity. Cost-efficiency initiatives commenced during FY26 are expected by management to continue into FY27.

International segment revenue rose approximately 15% to AUD 21.222 million from AUD 18.483 million. Underlying segment earnings before interest and tax increased to AUD 3.542 million from AUD 2.985 million, approximately 19% higher. Management identified activity in Malaysia as a contributor to international revenue growth. The smaller international segment was therefore moving differently from the larger Australian business.

Monash IVF (ASX:MVF) reported 5,753 clinical pregnancies during FY26 and 7,980 day-surgery procedures. It also disclosed increased genetics and ancillary income of AUD 4.6 million, linked to preimplantation genetic testing and storage fees. These activity measures provide context for revenue composition but do not by themselves indicate the profitability of each service.

Risks to Consider

Risks include patient demand, workforce availability, clinical quality, regulatory obligations and the cost of operating treatment facilities. The company has disclosed additional expenditure responding to incidents, making service governance and patient trust important operational matters. Higher finance costs and Capital Expenditure can also affect cash generation, particularly when domestic volumes or margins remain lower.

What to Watch Next

Monash IVF’s 2026 annual general meeting is scheduled for 26 November. Subsequent disclosures may clarify FY27 service activity, progress on Australian cost efficiencies, Investment in in-house surgical capacity and international clinic performance. Investors can also monitor reported versus underlying earnings and cash-flow outcomes.

Key Insights

Monash IVF (ASX:MVF) reported reduced FY26 group profitability despite international revenue expansion. The Australian segment accounted for most revenue and experienced notable cost pressure. FY27 execution, clinical governance and changes in operating expenses remain central monitoring points.